Co-morbid Conditions
The most common co-existing medical conditions of patients using biological agents were hypertension (18.1%), diabetes mellitus (7.3%), peptic ulcer (4.5%), chronic hepatitis B infection (4.3%), and depression (4.1%). Other co-morbid conditions reported were fatty liver (3.9%), previous pulmonary tuberculosis (3.7%), liver disease (2.7%), renal disease (2.6%), asthma (2.5%), hyperthyroidism (1.8%), ischemic heart disease (1.7%), cancer (1.4%), stroke (1.2%), congestive heart failure (0.8%), heart attack (0.7%), epilepsy (0.7%), previous extra-pulmonary tuberculosis (0.6%), COAD (0.5%), and chronic hepatitis C infection (0.4%).
Discontinuation of Treatment
The usage of biological agents is updated in Table 2 
Major Adverse Events Reported Neoplasia
There were 
Infection Requiring Hospitalization
There were 105 episodes of infective complications requiring hospitalization. About half of them occurred during the first 6 months of biological therapy.
Tuberculosis
A total of 56 cases of tuberculosis (TB) were reported: 31 related to Infliximab, 11 related to etanercept, 7 related to adalimumab, 4 related to golimumab, and 3 related to tocilizumab. Nearly 40% of the cases occurred in the first 6 months of treatment. There were 422 abnormal CXRs before treatment, and isoniazid chemoprophylaxis was given to 663 patients with latent TB as defined by a positive MT2 (≥10 mm induration). 
